Eledon Pharmaceuticals
ELDN
34 hedge funds and large institutions have $2M invested in Eledon Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 7 closing their positions.
18% less capital invested
Capital invested by funds: $2.43M → $2M (-$425K)
19% less funds holding
Funds holding: 42 → 34 (-8)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$464K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$68.5K |
| 3 |
SG Americas Securities
New York
|
+$59.8K |
| 4 |
Renaissance Technologies
New York
|
+$47.2K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$28.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$98K |
| 2 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$46K |
| 3 |
Goldman Sachs
New York
|
-$42.3K |
| 4 |
NSEDCP
NJ State Employees Deferred Compensation Plan
Trenton,
New Jersey
|
-$34K |
| 5 |
Morgan Stanley
New York
|
-$33.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MAM
26
Meeder Asset Management
Dublin,
Ohio
| $3K | -$4.85K | -33 | -62% |
|
27
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $3K | +$294 | +2 | +7% |
|
28
Bank of America
Charlotte,
North Carolina
| $1K | -$735 | -5 | -31% |
|
|
PAM
29
Panagora Asset Management
Boston,
Massachusetts
| $1K | +$882 | +6 | New |
|
|
BCM
30
Bridgeway Capital Management
Houston,
Texas
| – | -$98K | -617 | Closed |
|
|
AIM
31
Acrospire Investment Management
Chicago,
Illinois
| – | -$46K | -287 | Closed |
|
|
NSEDCP
32
NJ State Employees Deferred Compensation Plan
Trenton,
New Jersey
| – | -$34K | -216 | Closed |
|
33
Squarepoint
New York
| – | -$26K | -164 | Closed |
|
34
Millennium Management
New York
| – | -$22K | -142 | Closed |
|
35
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$20K | -124 | Closed |
|
36
Citigroup
New York
| – | -$8.96K | -61 | -98% |
|
37
UBS Group
Zurich,
Switzerland
| – | -$1.18K | -8 | -89% |
|
38
BNP Paribas Financial Markets
Paris,
France
| – | -$370 | -2 | Closed |
|
ELDN Hedge Fund Activity: Q1 2017 in Review
34 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2017, worth a combined $2M — down 18% from $2.43M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ELDN and 4 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 8 added.
The largest buyer was BlackRock, adding an estimated $464K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $98K sold.
- 34 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2017, down from 42 in Q4 2016.
- Funds reported $2M of Eledon Pharmaceuticals stock for Q1 2017, down 18% quarter-over-quarter.
- 4 funds opened new Eledon Pharmaceuticals positions in Q1 2017 and 7 closed out, a net change of -3 holders.
- The largest Eledon Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $464K added.
- The largest Eledon Pharmaceuticals seller in Q1 2017 was Bridgeway Capital Management, an estimated $98K sold.
Based on aggregated 13F filings for Q1 2017.